In previous work [21], we have generated a CAR specific for chondroitin sulfate proteoglycan 4 (CSPG4), also known as melanoma-associated chondroitin sulfate proteoglycan (MCSP), or high molecular weight melanoma-associated antigen (HMW-MAA), which is a cell-surface antigen expressed on 90% of melanoma primary tumors and metastases, but also on sarcomas, astrocytomas, gliomas, and neuroblastomas [22,23,24,25], and therefore we consider this an ideal target antigen. This evidence concerns the gene CSPG4 and central nervous system cancer.